Evidence map›Paper›PMID 36752813›Full record

ReviewEndocrine connections2023

An update on the long-term outcomes of prenatal dexamethasone treatment in congenital adrenal hyperplasia.

Annelies Van't Westeinde, Leif Karlsson, Valeria Messina, Lena Wallensteen, Manuela Brösamle, Giorgio Dal Maso, Alessandro Lazzerini, Jette Kristensen, Diana Kwast, Lea Tschaidse and 5 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Endocrine connections, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 5 countries.

Annelies Van't WesteindeDepartment of Women's and Children's Health, Karolinska Institutet and Division of Pediatrics, Unit for Pediatric Endocrinology and Metabolic Disorders, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0001-9208-3058
Leif KarlssonDepartment of Women's and Children's Health, Karolinska Institutet and Division of Pediatrics, Unit for Pediatric Endocrinology and Metabolic Disorders, Karolinska University Hospital, Stockholm, Sweden.
Valeria MessinaDepartment of Women's and Children's Health, Karolinska Institutet and Division of Pediatrics, Unit for Pediatric Endocrinology and Metabolic Disorders, Karolinska University Hospital, Stockholm, Sweden.
Lena WallensteenDepartment of Women's and Children's Health, Karolinska Institutet and Division of Pediatrics, Unit for Pediatric Endocrinology and Metabolic Disorders, Karolinska University Hospital, Stockholm, Sweden.
Manuela BrösamleEuropean Patient Advocacy Group for Adrenal Diseases, European Reference Network on Rare Endocrine Conditions (Endo ERN), Endo ERN Coordinating Centre, Leiden, The Netherlands.
Giorgio Dal MasoArfSAG (Associazione Refionale Famiglie Sindrome Adreno Genitale) c/o Unita Operativa di Pediatria, Azienda Ospedaliero Universitaria di Bologna, Policlinico S Orsala-Malpighi, Bologna, Italy.
Alessandro LazzeriniSpanish Association of Congenital Adrenal Hyperplasia (CAH), Spain.
Jette KristensenePAG & Chair of Danish Addison Patient Association, Aarhus, Denmark.
Diana KwastDutch Adrenal Society NVACP, Nijkerk, The Netherlands.
Lea TschaidseDepartment of Endocrinology, Medizinische Klinik IV, Klinikum der Universität München, Munich, Germany.
Matthias K AuerDepartment of Endocrinology, Medizinische Klinik IV, Klinikum der Universität München, Munich, Germany.
Hanna F NowotnyDepartment of Endocrinology, Medizinische Klinik IV, Klinikum der Universität München, Munich, Germany.
Luca PersaniDepartment of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy.ORCID 0000-0003-2068-9581
Nicole ReischDepartment of Endocrinology, Medizinische Klinik IV, Klinikum der Universität München, Munich, Germany.ORCID 0000-0002-7469-6069
Svetlana LajicDepartment of Women's and Children's Health, Karolinska Institutet and Division of Pediatrics, Unit for Pediatric Endocrinology and Metabolic Disorders, Karolinska University Hospital, Stockholm, Sweden.ORCID 0000-0002-4398-0948
Karolinska University Hospital · SELMU Klinikum · DEDanish Diabetes Association · DKDutch Cancer Society · NLEndo-ERN · NLIRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

First-trimester prenatal treatment with glucocorticoid (GC) dexamethasone (DEX) in pregnancies at risk for classic congenital adrenal hyperplasia (CAH) is associated with ethical dilemmas. Though effective in reducing virilisation in girls with CAH, it entails exposure to high doses of GC in fetuses that do not benefit from the treatment. The current paper provides an update on the literature on outcomes of prenatal DEX treatment in CAH cases and unaffected subjects. Long-term follow-up research is still needed to determine treatment safety. In addition, advances in early prenatal diagnostics for CAH and sex-typing as well as studies assessing dosing effects of DEX may avoid unnecessary treatment and improve treatment safety.

Indexed as

brain developmentCAHdexamethasonefirst trimesterprenatal treatmenttreatment safety

Identifiers

PMID36752813
PMCPMC10083667
OpenAlexW4319461076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.